Safety and efficacy of thymoglobulin (ATG) for cord blood transplantation for hematologic malignancies - Safety and efficacy of ATG for CBT for hematologic malignancies

Hematology, Osaka City University, Graduate School of Meicine0 个研究点目标入组 7 人开始时间: 2010年9月14日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1)Major organ dysfunction: (a)Ejection fraction: <30% (b)Pulmonary function test: %VC<30%, FEV1.0% <40%, or SaO2 <90% on room air (c)Serum creatinine: >2.0mg/dl (d)Liver function: total bilirubin >2.0mg/dl, AST or ALT >3 x UNL, or patients with chronic active hepatitis or liver cirrhosis (2)Poorly controlled hypertension (3)HIV antibody positivity (4)Uncontrolled active infection (5)Uncontrolled CNS invasion (6)Pregnant, nursing or possibly pregnant woman (7)Patients with severe mental disorder who are likely unable to participate in the study (8)Known hypersensitivity or allergy to any of the drugs in the conditioning regimen of this transplant, or drugs used for GVHD prophylaxis (9)Patients with positive donor-specific HLA antibodies(DSA) (10)Patients with graft failure following allegeneic hematopoietic stem cell transplantation (11)No indication for this study as judged by physician in charge. Note: HBs antigen positivity and HCV antibody positivity is not excluded.

发起方

Hematology, Osaka City University, Graduate School of Meicine